The FDA has granted ParagonDx clearance to market a genetic test that can detect the sensitivity of heart-attack and stroke patients to the blood thinner warfarin. The product, which is expected to be available in a few months, can cut the risk of excessive bleeding among patients taking warfarin.

Related Summaries